Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19

The aim of this study was to evaluate the impact of early treatment with corticosteroids on SARS-CoV-2 clearance in hospitalized COVID-19 patients. Retrospective analysis on patients admitted to the San Raffaele Hospital (Milan, Italy) with moderate/severe COVID-19 and availability of at least two nasopharyngeal swabs. The primary outcome was the time to nasopharyngeal swab negativization. A multivariable Cox model was fitted to determine factors associated with nasopharyngeal swab negativization. Of 280 patients included, 59 (21.1%) patients were treated with steroids. Differences observed between steroid users and non-users included the proportion of patients with a baseline PaO2/FiO(2)<= 200 mmHg (45.8% vs 34.4% in steroids and non-steroids users, respectively; p=0.023) or <= 100 mmHg (16.9% vs 12.7%; p=0.027), and length of hospitalization (20 vs 14 days; p<0.001). Time to negativization of nasopharyngeal swabs was similar in steroid and non-steroid users (p=0.985). According to multivariate analysis, SARS-CoV-2 clearance was associated with age70 years, a shorter duration of symptoms at admission, a baseline PaO2/FiO(2)>200 mmHg, and a lymphocyte count at admission>1.0x10(9)/L. SARS-CoV-2 clearance was not associated with corticosteroid use. Our study shows that delayed SARS-CoV-2 clearance in moderate/severe COVID-19 is associated with older age and a more severe disease, but not with an early use of corticosteroids.